Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
BioInvent International AB (BOVNF) and Transgene (TRGNF) have enrolled the first patient in a Phase I/IIa clinical trial evaluating BT-001 as a single agent and in combination with pembrolizumab (anti-PD-1 treatment). The Phase I will be divided into two parts:Part A will enrol...
BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors PR Newswire LUND, Sweden and STRASBOURG, France , March 1, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockh...
BioInvent International Financial Statement January 1 - December 31, 2020 Promising early interim efficacy data on our lead drug candidate PR Newswire LUND, Sweden , Feb. 23, 2021 /PRNewswire/ -- "BioInvent has started 2021 with significant positive momentu...
BioInvent International (BOVNF) and partner CASI Pharmaceuticals (CASI) announce positive interim results from the Phase I/IIa trial of novel anti-FcγRIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refr...
BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore activity of rituximab in non-Hodgkin's lymphoma pa...
Transgene (TRGNF) has received approval in France to proceed with a Phase I/IIa study of the novel oncolytic Vaccinia virus BT-001 developed with Invir.IO platform.This announcement follows approval received in December 2020 in Belgium. The first patient is expected to be enrolled in this tri...
BioInvent International AB (BOVNF) has announced that Pfizer has selected antibodies directed at a previously-selected target under the companies' cancer immunotherapy research collaboration and license agreement.The agreement, into which the companies entered in December 2016,...
BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors PR Newswire LUND, Sweden and STRASBOURG, France , Dec. 21, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech compa...
Nomination Committee appointed for BioInvent International's Annual General Meeting 2021 LUND, Sweden , Dec. 9, 2020 /PRNewswire/ -- The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent) Annual General Meeting in 2021 have now bee...
BioInvent strengthens Investor Relations PR Newswire LUND, Sweden, Nov. 27, 2020 LUND, Sweden , Nov. 27, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-...
News, Short Squeeze, Breakout and More Instantly...
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial...
LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimu...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...